Work

Ambroxol hydrochloride as an antibiofilm agent synergizes with tetracycline antibiotics against mature biofilms of multidrug-resistant Klebsiella pneumoniae

Year: 2025

Type: article

Abstract: Multidrug-resistant Klebsiella pneumoniae (MDR-KP) is a major pathogen responsible for hospital-acquired infections, associated with high morbidity and mortality. Biofilm formation plays a key role in the pathogenicity of MDR-KP and contributes significantly to its antibiotic resistance, substantially impairing the effectiveness of antimicrobial therapies. To enhance the efficacy of existing antibiotics, this study investigates a biofilm-targeting synergistic strategy inspired by the structural similarity between sputum and biofilm matrices. In this study, 87 clinical isolates of MDR-KP were initially screened for biofilm-forming capacity, and strong biofilm producers were selected to establish an in vitro model for systematic evaluation of the anti-biofilm efficacy of six mucolytic agents. Ambroxol hydrochloride (ABH) emerges as the optimal effective, disrupting biofilm structure at 0.7 mg/mL and achieving 50% clearance within 8 hours. ABH enhanced the anti-biofilm activity of tetracycline and doxycycline in vitro , reducing their IC 50 values by 98.9% and 98.6%, respectively, against preformed biofilms of MDR-KP compared to monotherapy. Additionally, the excellent physical and chemical compatibility between ABH and tetracycline or doxycycline provides a stable basis for in vivo co-administration. In vivo , the combination alleviates pulmonary inflammation, reduces bacterial load and inflammatory factor levels, and shows no tissue toxicity. In conclusion, ABH combined with tetracycline antimicrobials enhanced their efficacy against MDR-KP infections, especially biofilm-associated infections, in both in vitro and in vivo models, and possessed a favorable physicochemical compatibility and safety profile. These findings suggested that ABH-tetracycline therapy could represent a translationally promising and effective strategy for combating clinical MDR-KP infections.

Source: Biofilm

DOI: 10.1016/j.bioflm.2025.100315